A phase II multi-dose study of SGN-30 (anti-CD30 mAb) in patients with primary cutaneous anaplastic large cell lymphoma, large cell transformation of mycosis fungoides, and lymphomatoid papulosis

Trial Profile

A phase II multi-dose study of SGN-30 (anti-CD30 mAb) in patients with primary cutaneous anaplastic large cell lymphoma, large cell transformation of mycosis fungoides, and lymphomatoid papulosis

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs SGN 30 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 25 May 2011 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 25 May 2011 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 19 Dec 2006 Results have been reported
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top